Prognosis of Cerebral Vein and Dural Sinus Thrombosis
Прогноз тромбоза церебральных вен и дуральных синусов
2004-02-24
SCID: 54.1/mrw4c5vf
Discuss with AI
cerebral vein and dural sinus thrombosiscerebral venous thrombosis (CVT)modified Rankin Scale (mRS) outcomemultinational prospective observational studypredictors of death or dependence (age, sex, coma, mental status disorder, hemorrhage on CT, deep cerebral venous thrombosis, CNS infection, cancer)
Figures from the paper
Abstract (AI)
BACKGROUND AND PURPOSE: The natural history and long-term prognosis of cerebral vein and dural sinus thrombosis (CVT) have not been examined previously by adequately powered prospective studies. METHODS: We performed a multinational (21 countries), multicenter (89 centers), prospective observational study. Patients were followed up at 6 months and yearly thereafter. Primary outcome was death or dependence as assessed by modified Rankin Scale (mRS) score >2 at the end of follow-up. RESULTS: From May 1998 to May 2001, 624 adult patients with CVT were registered. At the end of follow-up (median 16 months), 356 patients (57.1%) had no symptom or signs (mRS=0), 137 (22%) had minor residual symptoms (mRS=1), and 47 (7.5%) had mild impairments (mRS=2). Eighteen (2.9%) were moderately impaired (mRS=3), 14 (2.2%) were severely handicapped (mRS=4 or 5), and 52 (8.3%) had died. Multivariate predictors of death or dependence were age >37 years (hazard ratio [HR]=2.0), male sex (HR=1.6), coma (HR=2.7), mental status disorder (HR=2.0), hemorrhage on admission CT scan (HR=1.9), thrombosis of the deep cerebral venous system (HR=2.9), central nervous system infection (HR=3.3), and cancer (HR=2.9). Fourteen patients (2.2%) had a recurrent sinus thrombosis, 27 (4.3%) had other thrombotic events, and 66 (10.6%) had seizures. CONCLUSIONS: The prognosis of CVT is better than reported previously. A subgroup (13%) of clinically identifiable CVT patients is at increased risk of bad outcome. These high-risk patients may benefit from more aggressive therapeutic interventions, to be studied in randomized clinical trials.
Key Findings
1
Conclusion: Prognosis of CVT is better than previously reported, but a clinically identifiable high-risk subgroup (~13%) has increased risk of poor outcome and might benefit from more aggressive treatments tested in randomized trials.
2
In a prospective multinational cohort of 624 adults with CVT (median follow-up 16 months), 57.1% had no symptoms (mRS=0) and 22% had minor residual symptoms (mRS=1).
3
Multivariate predictors of death or dependence included age >37 years (HR=2.0), male sex (HR=1.6), coma (HR=2.7), mental status disorder (HR=2.0), hemorrhage on admission CT (HR=1.9), deep cerebral venous system thrombosis (HR=2.9), CNS infection (HR=3.3), and cancer (HR=2.9).
4
Overall outcomes: 7.5% had mild impairments (mRS=2), 2.9% moderately impaired (mRS=3), 2.2% severely handicapped (mRS=4 or 5), and 8.3% died.
5
Recurrent events and complications: 2.2% had recurrent sinus thrombosis, 4.3% had other thrombotic events, and 10.6% experienced seizures.
Research Object
Adult patients with cerebral vein and dural sinus thrombosis (CVT) enrolled in a multinational prospective observational study
Research Subject
Long-term prognosis and clinical outcomes (death or dependence by modified Rankin Scale), incidence of recurrent thrombosis and complications, and predictors of poor outcome in CVT patients
Publication Details
Publication Date
2004-02-24
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest